A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled

The Quick Take
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to CNBC Top News.
Related
Markets
JBT Marel raises adjusted EPS guidance midpoint, trims 2026 revenue outlook
Markets
Xenia Hotels FFO of $0.36 beats by $0.05, revenue of $263.8M beats by $6.89M
Markets
Palantir selloff puts ETFs with heavy PLTR exposure in focus
Markets
Объем торгов на Bitget достиг $1,86 трлн в III квартале 2026 года
Криптовалютная биржа Bitget опубликовала отчет о прозрачности за III квартал 2026 года, согласно которому совокупный объем торгов на платформе достиг $1,86…
